31 may 2022 (Tuesday) - Stem Cell Evidence Alert

The monthly Stem Cell Evidence Alert came today. I haven’t mentioned this one for a while, but one or two of the articles referring to bone marrow transplants were enlightening.


In-vivo T-cell depleted reduced-intensity conditioned allogeneic haematopoietic stem-cell transplantation for patients with acute lymphoblastic leukaemia in first remission: results from the prospective, single-arm evaluation of the UKALL14 trial.Marks, D.I., et al. (2022) The Lancet. Haematology.  9(4):e276-e288.PICO SUMMARY



Hematopoietic stem cell transplantation for adolescents and adults with inborn errors of immunity, an EBMT IEWP study. Albert, M. H., et al. (2022) Blood [record in progress]Myeloablative conditioning with thiotepa-busulfan-fludarabine does not improve the outcome of patients transplanted with active leukemia: final results of the GITMO prospective trial GANDALF-01.Bonifazi, F. et al. (2022) Bone Marrow Transplantation [record in progress]Adding bendamustine to melphalan before ASCT improves CR rate in myeloma vs. melphalan alone: A randomized phase-2 trial.Farag, S., et al. (2022) Bone Marrow Transplantation [record in progress]Neutralizing antibody and T cell responses to SARS-CoV-2 vaccination in hematopoietic cell transplant recipients.Gavriilaki, E., et al. (2022) Bone Marrow Transplantation [record in progress]Feasibility and efficacy of partially replacing post-transplant cyclophosphamide with bendamustine in pediatric and young adult patients undergoing haploidentical bone marrow transplantationKatsanis, E., et al. (2022) Transplantation and Cellular Therapy [record in progress]Narsoplimab, a Mannan-Binding Lectin-Associated Serine Protease-2 Inhibitor, for the Treatment of Adult Hematopoietic Stem-Cell Transplantation-Associated Thrombotic Microangiopathy.Khaled, S. K., et al. (2022) Journal of Clinical Oncology: Jco2102389.Busulfan, Melphalan, and Etoposide (BuMe) Showed an Equivalent Effect to Busulfan, Cyclophosphamide, and Etoposide (BuCE) as Conditioning Therapy for Autologous Stem Cell Transplantation in Patients with Relapsed or High Risk Non-Hodgkin's Lymphoma: A Multicenter Randomized Phase II Study by the Consortium for Improving Survival of Lymphoma (CISL).Kim, K.H., et al. (2022) Cancer Research and Treatment [record in progress]Mesenchymal Stromal Cells for Treating Steroid-Resistant Acute and Chronic Graft Versus Host Disease: A Multicenter Compassionate Use Experience.Macías-Sánchez, M. D. M., et al. (2022) Stem Cell Translational Medicine [record in progress]Evaluation of the pharmacokinetic interaction between letermovir and tacrolimus in allogeneic hematopoietic cell transplant recipients.Marciano, K. A., et al. (2022) Transplantation and Cellular Therapy [record in progress]

No comments:

Post a Comment